CUHK-led international study confirms rituximab reduces disease relapses in young children with nephrotic syndrome, paving the way for second-line treatment options
October 08, 2026
October 08, 2026
SHATIN, Hong Kong, Oct. 8 -- The Chinese University of Hong Kong posted the following news release:
* * *
CUHK-led international study confirms rituximab reduces disease relapses in young children with nephrotic syndrome, paving the way for second-line treatment options
*
Nephrotic syndrome (NS) is the most common glomerular disease in childhood, with over two-thirds of affected children suffering from repeated relapses, requiring high dose ste . . .
* * *
CUHK-led international study confirms rituximab reduces disease relapses in young children with nephrotic syndrome, paving the way for second-line treatment options
*
Nephrotic syndrome (NS) is the most common glomerular disease in childhood, with over two-thirds of affected children suffering from repeated relapses, requiring high dose ste . . .
